Morristown Medical Center, Overlook Medical Center, Chilton Medical Center, and Newton Medical Center Quality Measures

The National Cancer Data Base (NCDB), a joint program of the Commission on Cancer (CoC) of the American College of Surgeons (ACoS) and the American Cancer Society (ACS), is a nationwide oncology outcomes database for more than 1,500 Commission-accredited cancer programs in the United States and Puerto Rico. This data is used to explore trends in cancer care, to create regional and state benchmarks for participating hospitals, and to serve as the basis for quality improvement.

Morristown, Overlook, Chilton, and Newton medical centers participates in this program and reports our data to the CoC and ACoS, and the most recent report covers patients diagnosed in 2016. The four quality measures for breast cancer are below.

Learn more about the CoC's quality of care measures >

Quality Measures As Reported Among CoC Approved Cancer Programs, Diagnosis Year 2016

	Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conservation surgery for breast cancer	Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0, or Stage IB-III hormone negative breast cancer	Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c, or Stage IB-III hormone positive breast cancer	Radiation therapy is considered or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with >= 4 positive regional lymph nodes
Morristown Medical Center	95%	100%	97.8%	92.3%
Overlook Medical Center	92.7%	93.3%	95.9%	100%
Chilton Medical Center	100%	100%	95.2%	100%
Newton Medical Center	85%	100%	94.7%	100%
State: New Jersey	91.6%	88.4%	92.8%	90%
National	91.8%	93.2%	92.8%	88.3%

Many factors are considered before post-operative (adjuvant) chemotherapy is given. If a patient has other medical illnesses that would make chemotherapy dangerous, or if a patient refuses a recommendation for treatment, the percentages above will be lower.

